top of page
Carmi Lab
Cancer Immunobiology and Immunotherapy
ABOUT US
Yaron Carmi, PhD
Principal investigator
Dr. Carmi worked as a postdoctoral fellow at Stanford University with Prof. Edgar G. Engleman, where he focused on understanding the key factors by which tumor-associated dendritic cells process molecules as foreign antigens.
He completed his PhD studies summa cum laude at the Immunology Department in Ben-Gurion University, under the supervision of Prof. Ron N. Apte and won a number of academic excellence awards. He studied Biotechnology in Tel-Hai Collage, where he worked under the supervision of Prof. Gidi Gross, one of the researchers who developed the chimeric T cell receptor (CAR) therapy.
​
Peleg Rider, PhD
Lab manager
Dr. Peleg Rider received his Ph.D from the Department of Immunology in Ben-Gurion University, under the supervision of prof. Ron N. Apte. His research focused on the role of the inflammatory cytokines IL-1alpha and IL-1beta in the sterile inflammatory process. In his post-Doc research, Peleg developed an anti-inflammatory protein, which is activated by the inflammatory process, known as “chimeric-IL-1Ra”, under the supervision of prof. Lewis from BGU and prof. Dinarello from the university of Colorado.

​
Nadin Santana-Magal
PhD candidate
Mrs Santana-Magal holds an engineering degree in biotechnology from the Tachnion and a M.Sc. in life science from Tel-Aviv University. Her PhD thesis focus on the route of antigen presentation by DC subsets during tumor progression and following immunotherapy.
​
Diana Rasoloniriana
PhD candidate
Mrs Rasoloniriana holds an engineering degree in biotechnology from Ben-Gurion University of the Negev and a M.Sc. in life science from Ben-Gurion University. Her PhD thesis focus on isolating CD4 tumor-reactive T cells and on identify the checkpoints that regulate their activation during tumor progression and immunotherapy.
​
Amit Gutwilling
PhD. candidate
Mr. Gutwilling has discovered a unique subset of cancer cells, in both mice and humans, which can resistant to CD8+ T cell-mediated killing. These cells maintain high MHCI levels and do not lose their T cell-reactive antigen.
Leen Farhat
MD/Ph.D. candidate
Mrs. Farahat works to generate immunotherapy that is based on monocytes bearing chimeric antigen receptors. She has discovered a unique signaling cascade in monocytes which can be harnessed to kill tumor cells.
bottom of page